WS Investor
23 Mar 2026, 22:08
Pfizer and Valneva announced positive Phase 3 results for their Lyme disease vaccine candidate, showing efficacy above 70% in preventing the disease in individuals aged five and older.
The investigational vaccine demonstrated strong efficacy of around 73–75% in key analyses and was well tolerated with no major safety concerns, supporting plans for regulatory submissions.
The results mark a significant step toward the first approved human vaccine for Lyme disease, addressing a growing unmet medical need in North America and Europe.
The investigational vaccine demonstrated strong efficacy of around 73–75% in key analyses and was well tolerated with no major safety concerns, supporting plans for regulatory submissions.
The results mark a significant step toward the first approved human vaccine for Lyme disease, addressing a growing unmet medical need in North America and Europe.